Fractyl Health, Inc. (NASDAQ:GUTS) Sees Large Growth in Short Interest

Fractyl Health, Inc. (NASDAQ:GUTS) was the recipient of a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,570,000 shares, an increase of 16.3% from the December 15th total of 2,210,000 shares. Currently, 12.5% of the shares of the stock are sold short. Based on an average daily volume of 330,200 shares, the days-to-cover ratio is currently 7.8 days.

Fractyl Health Price Performance

GUTS stock traded down $0.01 during mid-day trading on Friday, hitting $1.80. 236,286 shares of the stock were exchanged, compared to its average volume of 265,966. The business has a fifty day moving average price of $2.11 and a 200 day moving average price of $2.69. Fractyl Health has a 12 month low of $1.74 and a 12 month high of $14.50. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.58 and a quick ratio of 5.57. The stock has a market capitalization of $86.58 million and a price-to-earnings ratio of -0.15.

Fractyl Health (NASDAQ:GUTS) last released its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.02. The firm had revenue of $0.01 million during the quarter. On average, sell-side analysts anticipate that Fractyl Health will post -1.66 EPS for the current year.

Insider Transactions at Fractyl Health

In other news, CEO Harith Rajagopalan sold 96,517 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99. Following the sale, the chief executive officer now owns 491,329 shares in the company, valued at approximately $1,213,582.63. This trade represents a 16.42 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jay David Caplan sold 64,197 shares of Fractyl Health stock in a transaction on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the sale, the insider now directly owns 153,544 shares of the company’s stock, valued at $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Institutional Investors Weigh In On Fractyl Health

Institutional investors have recently made changes to their positions in the business. Jane Street Group LLC purchased a new position in Fractyl Health in the 3rd quarter worth $25,000. Rhumbline Advisers purchased a new position in shares of Fractyl Health in the second quarter worth about $32,000. SG Americas Securities LLC bought a new stake in shares of Fractyl Health in the 3rd quarter valued at about $33,000. JPMorgan Chase & Co. lifted its stake in shares of Fractyl Health by 335.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock valued at $37,000 after acquiring an additional 11,406 shares during the last quarter. Finally, HighTower Advisors LLC purchased a new stake in Fractyl Health during the 3rd quarter valued at about $38,000.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.